Dal Pra Chiara, Chen Shu, Betterle Corrado, Zanchetta Renato, McGrath Vivienne, Furmaniak Jadwiga, Rees Smith Bernard
FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff CF14 5DU, UK.
Eur J Endocrinol. 2004 Mar;150(3):313-21. doi: 10.1530/eje.0.1500313.
To assess the prevalence of autoantibodies (Abs) to tryptophan hydroxylase (TPH) and aromatic l-amino acid decarboxylase (AADC) in patients with different autoimmune diseases and to analyse their respective epitopes.
TPH and AADC Abs were measured in an immunoprecipitation assay using (35)S-labelled full-length and fragments of TPH and AADC.
Patients with different autoimmune adrenal diseases (n=84), non-adrenal autoimmune diseases (n=37), idiopathic vitiligo (n=8) and 56 healthy blood donors were studied.
Fourteen of twenty-three (61%) of patients with autoimmune polyglandular syndrome (APS) type I and 1/34 (3%) of patients with isolated Addison's disease (AD) were positive for TPH Abs. None of the patients with APS type II (n=27), coeliac disease (n=10), autoimmune thyroid disease (AITD) (n=11), type 1 diabetes mellitus (DM) (n=16) or idiopathic vitiligo (n=8) was positive for TPH Abs. AADC Abs were detected in 12/23 (52%) patients with APS type I, in 1/29 (3%) patients with APS type II and 1/34 (3%) patients with isolated AD. None of the patients with coeliac disease, type 1 DM, AITD or idiopathic vitiligo was positive for AADC Abs. TPH Abs were found to interact with the C-terminal amino acids (aa) 308-423, central aa 164-205 and N-terminal aa 1-105 of the TPH molecule. AADC Ab binding epitopes were within the C-terminal aa 382-483, the central aa 243-381 and the N-terminal aa 1-167.
Our study suggests that TPH Abs and AADC Abs react with several different epitopes and that different epitopes are recognized by different sera. The prevalence of TPH Abs and AADC Abs in patients with APS type I in our study is in agreement with previous reports. TPH Abs and AADC Abs were found very rarely in patients with other forms of autoimmune adrenal disease and were not detected in patients with non-adrenal autoimmune diseases.
评估不同自身免疫性疾病患者中色氨酸羟化酶(TPH)和芳香族L-氨基酸脱羧酶(AADC)自身抗体(Abs)的患病率,并分析它们各自的表位。
使用(35)S标记的TPH和AADC全长及片段,通过免疫沉淀试验检测TPH和AADC抗体。
研究了不同自身免疫性肾上腺疾病患者(n = 84)、非肾上腺自身免疫性疾病患者(n = 37)、特发性白癜风患者(n = 8)以及56名健康献血者。
23例I型自身免疫性多内分泌腺综合征(APS)患者中有14例(61%)TPH抗体呈阳性,34例孤立性艾迪生病(AD)患者中有1例(3%)TPH抗体呈阳性。II型APS患者(n = 27)、乳糜泻患者(n = 10)、自身免疫性甲状腺疾病(AITD)患者(n = 11)、1型糖尿病(DM)患者(n = 16)或特发性白癜风患者(n = 8)中,均无TPH抗体呈阳性。12/23(52%)例I型APS患者、1/29(3%)例II型APS患者和1/34(3%)例孤立性AD患者检测到AADC抗体。乳糜泻、1型DM、AITD或特发性白癜风患者中,均无AADC抗体呈阳性。发现TPH抗体与TPH分子的C末端氨基酸(aa)308 - 423、中央aa 164 - 205和N末端aa 1 - 105相互作用。AADC抗体结合表位位于C末端aa 382 - 483、中央aa 243 - 381和N末端aa 1 - 167范围内。
我们的研究表明,TPH抗体和AADC抗体与几种不同的表位发生反应,且不同血清识别不同的表位。我们研究中I型APS患者中TPH抗体和AADC抗体的患病率与先前报道一致。在其他形式的自身免疫性肾上腺疾病患者中很少发现TPH抗体和AADC抗体,在非肾上腺自身免疫性疾病患者中未检测到。